TrialSignal
Clinical trial intelligence report
Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03604289-Jul 28, 2026
NCT ID
NCT03604289
Status
TERMINATED
Phase
EARLY_PHASE1
Sponsor
Amy Arnold
Executive brief
Investment-Ready Snapshot
Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension is a EARLY_PHASE1 clinical asset sponsored by Amy Arnold in Obesity, Hypertension. SEO and diligence focus: Angiotensin-(1-7), Saline, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03604289
Indication
Obesity
Modality
protein therapy
Target
Angiotensin-(1-7), Saline
Intervention
Angiotensin-(1-7), Saline
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.